Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025
As of this afternoon, Galmed Pharmaceuticals shares were changing hands around $1.18, up roughly 13% on the day, with more than 41 million shares traded—massively above the stock’s usual daily volume. TipRanks What Galmed Announced Today From its headquarters in Ramat Gan, Israel, Galmed Pharmaceuticals Ltd. announced fresh results from its ongoing collaboration with Virginia Commonwealth University (VCU) on overcoming drug resistance in GI cancers. Galmed Pharmaceuticals+1 The headline: A three‑drug combination of Aramchol + Stivarga + metformin produced a synergistic anti‑tumor effect, significantly enhancing GI tumor cell killing both in vitro and in vivo. According to today’s press release